The trajectory of Sildenafil presents a intricate picture for investors. While the initial introduction generated significant gains, the lapse of its patent opened the door to off-brand competitors, dramatically reducing revenue. This poses a particular risk for pharmaceutical companies banking on related blockbuster medications, suggesting that a

The legacy of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, yielding billions in sales , its patent expiration created a deluge of knock-off medications, significantly eroding its dominance. While some businesses may try to capitalize on similar conditions , the current landscape